- Home
- BFST vs GYRE Comparison
BFST vs GYRE Comparison
Compare BFST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- GYRE
- Stock Information
- Founded
- BFST 2006
- GYRE 2002
- Country
- BFST United States
- GYRE United States
- Employees
- BFST N/A
- GYRE N/A
- Industry
- BFST Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- GYRE Health Care
- Exchange
- BFST Nasdaq
- GYRE Nasdaq
- Market Cap
- BFST 783.9M
- GYRE 897.1M
- IPO Year
- BFST 2018
- GYRE N/A
- Fundamental
- Price
- BFST $25.16
- GYRE $7.69
- Analyst Decision
- BFST Strong Buy
- GYRE Strong Buy
- Analyst Count
- BFST 3
- GYRE 1
- Target Price
- BFST $30.00
- GYRE $18.00
- AVG Volume (30 Days)
- BFST 88.3K
- GYRE 92.4K
- Earning Date
- BFST 10-23-2025
- GYRE 08-11-2025
- Dividend Yield
- BFST 2.23%
- GYRE N/A
- EPS Growth
- BFST 3.92
- GYRE N/A
- EPS
- BFST 2.51
- GYRE 0.02
- Revenue
- BFST $291,096,000.00
- GYRE $102,189,000.00
- Revenue This Year
- BFST $25.00
- GYRE $21.04
- Revenue Next Year
- BFST $17.32
- GYRE $89.64
- P/E Ratio
- BFST $10.01
- GYRE $167.70
- Revenue Growth
- BFST 17.48
- GYRE N/A
- 52 Week Low
- BFST $20.07
- GYRE $6.11
- 52 Week High
- BFST $30.30
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- BFST 55.16
- GYRE 49.20
- Support Level
- BFST $24.67
- GYRE $7.02
- Resistance Level
- BFST $25.61
- GYRE $8.12
- Average True Range (ATR)
- BFST 0.54
- GYRE 0.52
- MACD
- BFST 0.11
- GYRE -0.02
- Stochastic Oscillator
- BFST 67.89
- GYRE 48.55
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.